# Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)

Source: https://onco.cc/trials/nct05534087/  
OnCo record `nct05534087` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in colorectal cancer, run by Seoul National University Hospital, now recruiting.

## Summary

Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12) is a phase 3, randomised interventional study registered as NCT05534087 by Seoul National University Hospital, with a registry enrolment figure of 236 participants, started 2022-12-15 and due to reach its primary completion in 2028-09-30. Interventions recorded: mFOLFIRINOX-FOLFIRI intensified chemotherapy; FOLFOX or CAPOX adjuvant chemotherapy. Conditions listed: Colon Cancer. Primary outcome: 3-year disease-free survival rate. Colorectal eligibility wording from the registry: "Adenocarcinoma of colon confirmed by histology". Sites: South Korea. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: CLAUDIA
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05534087
- Phase: 3
- Setting: A Randomized Controlled Phase III Trial of Treatment Intensification in Stage II-III Colon Cancer Patients With Positive MRD During Adjuvant Chemotherapy
- Sponsor: Seoul National University Hospital
- Enrolled: 236

## Sources

- ClinicalTrials.gov NCT05534087: https://clinicaltrials.gov/study/NCT05534087

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/)
- technologies: [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05534087.json